CONTOURA vs WFO Ablation PRK & LASIK

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-50
Sponsor59th Medical Wing

About this trial

This is a prospective randomized contralateral double-masked study. Each patient will be randomized as to which eye undergoes wave-front optimized (WFO) vs. wave-front guided (WFG) during Photorefractive keratectomy (PRK) or Laser-assisted in situ Keratomileusis (LASIK) surgery to determine which ablation profile provides the best visual outcome.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Meet requirements for PRK or LASIK i.e., Stable <= .5 D change MRSE)

DOD beneficiaries age 21-50 years

Local pts (w/i 60 mi) who will be in the area for at least 6 months post surgery

Willing to complete all required follow-up visits

Disqualifiers

No meeting requirements for PRK or LASIK

Desiring monovision treatment

Anisometropia >2D spherical equivalent

Prior ocular surgeries / trauma / problem

Trial design

Design model

Parallel

Treatments tested in this trial

  • Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation

    Device

    Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye

Treatment groups

400 Participants
are divided into 2 treatment groups
Group A: LASIK refractive surgeryExperimental treatment 1 intervention
Group B: PRK refractive surgeryExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Post-operative refractive error

The Post-Operative sphere equivalent refractive error for eyes undergoing Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

Time frame
6 months post-surgery

Secondary outcomes

1

Post-operative Uncorrected Visual Acuity

The Post-Operative visual acuity for eyes undergoing Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

Time frame
6 months post-surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.